Physician profile
Hailey Farmer
NPI 1003383746
$4,736.70
in general payments reported to CMS, 2019-2025
34 companies · $3,064 in 2025
The $3,064 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $17.30 · 2022: $498 · 2023: $263 · 2024: $894 · 2025: $3,064.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,163 · Education: $58.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,162.65 |
| Education | $58.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $871.65 | 2024-2025 | Airsupra, Tezspire, Breztri |
| Regeneron Healthcare Solutions, INC. | $540.94 | 2024-2025 | Dupixent |
| Csl Behring | $476.82 | 2024-2025 | Hizentra, Haegarda |
| Ars Pharmaceuticals Operations, INC. | $327.97 | 2025 | Neffy |
| Genzyme Corporation | $276.39 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $264.84 | 2024-2025 | |
| Glaxosmithkline, LLC. | $255.88 | 2024-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astellas Pharma US INC | $242.38 | 2022-2024 | Veozah, Myrbetriq |
| Amgen INC. | $206.41 | 2024-2025 | Tezspire |
| Urovant Sciences INC | $130.07 | 2022 | |
| Pfizer INC. | $129.09 | 2022-2023 | |
| Genentech USA, INC. | $126.70 | 2024-2025 | Xolair |
| Blueprint Medicines Corporation | $100.97 | 2025 | Ayvakit |
| Abbvie INC. | $80.88 | 2021-2025 | |
| Cycle Pharmaceuticals INC | $74.96 | 2025 | Sajazir |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $74.83 | 2024-2025 | Xembify |
| Galderma Laboratories, L.P. | $59.47 | 2025 | Nemluvio |
| Daiichi Sankyo INC. | $50.17 | 2022 | |
| Gc Biopharma USA, INC. | $49.80 | 2025 | Alyglo |
| Mayne Pharma Commercial LLC | $42.89 | 2022 | |
| Organon LLC | $42.74 | 2025 | Vtama |
| Bayer Healthcare Pharmaceuticals INC. | $35.47 | 2023 | |
| Sumitomo Pharma America, INC. | $31.90 | 2023-2024 | Gemtesa |
| Hikma Pharmaceuticals USA | $31.01 | 2024-2025 | Ryaltris |
| Pharming Healthcare, INC. | $29.13 | 2025 | Ruconest |
| Mylan Pharmaceuticals INC. | $25.15 | 2022 | |
| Lilly USA, LLC | $24.05 | 2025 | Ebglyss |
| Octapharma USA, INC. | $23.09 | 2025 | Octagam Immune Globulin (Human) |
| Baxter Healthcare | $22.11 | 2022 | |
| Kaleo, INC. | $20.62 | 2024 | Auvi-Q |
| Scynexis, INC. | $18.34 | 2022 | |
| Myovant Sciences INC. | $17.00 | 2022 | |
| Sage Therapeutics, LLC | $16.60 | 2024 | |
| Shield Therapeutics INC | $16.38 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hailey Farmer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.